Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2019 07:05 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,...
February 11, 2019 07:00 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics...
January 03, 2019 07:00 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer

SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,...
January 02, 2019 07:00 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,...
December 03, 2018 07:00 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11

SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,...
November 07, 2018 07:00 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results

SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,...
November 05, 2018 07:00 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility

SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, will officially cut the ribbon on its San Diego based research and...
October 01, 2018 07:09 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

SAN DIEGO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,...
September 25, 2018 07:00 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics to Present at October Investor Conferences

SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced that Joseph Payne will present at four investor conferences...
September 21, 2018 07:00 ET | Source: Arcturus Therapeutics, Inc.

Arcturus Therapeutics Expands Management Team

Arcturus Appoints Senior VP of Business Development & Alliance Management and VP of Translational Biology SAN DIEGO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:...